Fibrocell’s gene therapy FCX-007 shows positive effect in RDEB study; shares up 4% – Seeking Alpha
|
Fibrocell's gene therapy FCX-007 shows positive effect in RDEB study; shares up 4%
Seeking Alpha Preliminary data from a Phase 1/2 study evaluating Fibrocell Science's (FCSC +3.7%) gene therapy, FCX-007, in patients with recessive dystrophic epidermolysis bullosa (RDEB) showed a treatment effect. The data were presented at the International … FIBROCELL SCIENCE, INC. (NASDAQ:FCSC) Files An 8-K Other Events |
